We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Lifeline Sci. S | LSE:LSI | London | Ordinary Share | COM SHS USD0.01 (REG S) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 137.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jun 2019 to Jun 2024
TIDMLSI TIDMLSIC
RNS Number : 4756E
Lifeline Scientific, Inc
10 April 2014
Lifeline Scientific
("Lifeline" or the "Company")
Notice of Results and Analyst & Investor briefings
Lifeline Scientific (AIM: LSIC, LSI), the transplantation technology company, will be reporting its preliminary results for the year ended 31 December 2013 on Tuesday 29 April 2014.
Analyst briefing
David Kravitz (CEO) and Lisa Kieres (CFO) will be hosting a briefing for analysts on Tuesday 29 April 2014 at 11.00am at the offices of Panmure Gordon & Co., One New Change, London EC4M 9AF.
Investor briefing
The management team will also be presenting the Company's financial and operational results for investors on the evening of Tuesday 29 April 2014. The event is open to investors and will be held at Panmure Gordon & Co., One New Change, London EC4M 9AF, from 16:30 for a 16:45 start. LifePort Kidney Transporter and LifePort Liver Transporter (a commercial prototype) will be available to view at the briefings.
For more information or to register to attend either event contact Walbrook PR (contact details below).
For further information, please contact:
Walbrook PR Ltd Tel: 020 7933 8780 or lifeline@walbrookpr.com Lianne Cawthorne Mob: 07584 391 303 Anna Dunphy Mob: 07876 741 001
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the market-leading and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart and lung are in late stage pre-clinical development. For more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. Today, it is widely recognised as the world's leading machine preservation device for kidneys. Employed by surgeons in over 160 leading transplant programmes in 27 countries worldwide, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com
Lifeline Scientific, Inc. Shares
As a US Company listed on the London Stock Exchange's AIM exchange, Lifeline Scientific, Inc. (AIM: LSIC, LSI) trades under two lines of stock. While affiliates of the Company are required to hold restricted (RegS) shares, all others may hold restricted or unrestricted shares. Unrestricted shares may be electronically traded through the CREST system. Both lines of stock have identical rights, preferences and privileges. Non-affiliates may transfer restricted shares to the unrestricted line after purchase through the Company's registrar. Total shares outstanding for the Company at this time are 19,446,959.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUUCCUPCGAB
1 Year Lifeline Sci. S Chart |
1 Month Lifeline Sci. S Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
